PALVELLA THERAPEUTICS, INC.
Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing novel therapies for serious, rare skin diseases and vascular malformations that currently lack FDA-approved treatment options. The company's website is www.palvella.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What PALVELLA THERAPEUTICS, INC. does
In the company’s own words
Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing novel therapies for serious, rare skin diseases and vascular malformations that currently lack FDA-approved treatment options. The company's website is www.palvella.com.
On December 13, 2024, Palvella completed a merger with Legacy Palvella Therapeutics, Inc., following which the combined entity changed its name from Pieris Pharmaceuticals, Inc. to Palvella Therapeutics, Inc. The merger marked a strategic pivot toward rare dermatological and vascular disease treatment development.
The company's primary focus centers on its proprietary QTORIN platform, a patented anhydrous gel formulation technology designed to deliver therapeutic agents to deep skin layers while minimizing systemic absorption. QTORIN rapamycin, the company's lead product candidate, is in clinical development for microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. In February 2026, the company announced positive Phase 3 results from the SELVA trial for microcystic lymphatic malformations, with the primary endpoint met at statistical significance. The company also reported positive Phase 2 results from the TOIVA trial for cutaneous venous malformations in December 2025.
Beyond QTORIN rapamycin, Palvella announced QTORIN pitavastatin in November 2025, a new product candidate designed to treat disseminated superficial actinic porokeratosis by targeting the mevalonate pathway. The company has received multiple FDA designations including Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation for QTORIN rapamycin in microcystic lymphatic malformations. Additionally, the company received an FDA Orphan Products Clinical Trials Grant supporting development efforts.
The company's strategy includes building an independent commercial organization to market approved therapies in the United States through a focused specialty sales force targeting vascular anomaly centers and dermatologists. Palvella plans to submit a New Drug Application for QTORIN rapamycin in the second half of 2026 and intends to expand its pipeline into additional rare skin diseases and vascular malformations leveraging the QTORIN platform's versatility across multiple therapeutic molecules.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- WAYNE, PA
- Fiscal year end
- December
- CIK
- 1583648
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns PALVELLA THERAPEUTICS, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · PALVELLA THERAPEUTICS, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do PALVELLA THERAPEUTICS, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of PALVELLA THERAPEUTICS, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in PALVELLA THERAPEUTICS, INC.'s last four quarterly filings that the numbers alone won't show?”